Skip to main content

Afamitresgene Autoleucel Dosage

Medically reviewed by Drugs.com. Last updated on Sep 17, 2024.

Usual Adult Dose for Soft Tissue Sarcoma

2.68 x 10(9) to 10 x 10(9) melanoma-associated antigen A4 (MAGE-A4) T cell receptor positive T cells

Comments:


Use: For the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING(S):
Cytokine Release Syndrome (CRS):
CRS, which may be severe or life-threatening, has been reported following administration of this drug. At the first sign of CRS, immediately evaluate patients for hospitalization and institute treatment with supportive care. Ensure that medications and resuscitative equipment is available on site prior to infusion of this drug to manage potential CRS.

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.